Drugs / TAF
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05005507 Background | Nov → Dec 2021 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05005507 ↗ |
| Route | Oral | “TAF film-coated tablet will be administered orally once daily.” NCT05005507 ↗ |